In a randomized, multicenter, open-label study of Asian patients with advanced HCC, the phase I portion, patients were divided into two groups based on baseline alanine aminotransferase/aspartate aminotransferase (ALT/AST) and Child-Pugh score (group I: ALT and AST ≤ 2 times the upper limit of normal (ULN) and Child-Pugh score 5-6; group II: ALT or AST>2 to ≤5 times the ULN or Child-Pugh score 7), and the maximum tolerated dose (MTD) of 200 mg was determined for both groups (63). This evidence concerns the gene GPT and hepatocellular carcinoma.